The value of Age-Related Macular Degeneration has clearly stood the test of time, but progress in both basic and clinical ophthalmology has been relentless, thereby mandating the need for an updated book.
The physicians, scientists, and patients who read this Third Edition will be reassured that this markedly enhanced edition has met the challenge of providing new information that is both intellectually and clinically valuable. Dr. Lim has again chosen expert authors for the important topics in this stimulating compendium.
Chapters are devoted to the following: pathophysiology and epidemiology of age-related macular degeneration (AMD), clinical features of AMD, imaging techniques, and medical therapy for both non-neovascular AMD and neovascular AMD. Both clinically validated and experimental therapies are well described, including rehabilitation technology (a highly important topic that is often overlooked in the management of patients with AMD).
Key features of this new edition:
‧Over 200 clinical photographs and illustrations (many in full colour)
‧An in-depth review and analysis of the management of dry and wet AMD (medical and surgical therapies)
‧Research advancements that have resulted in novel therapies
‧Strategies to prevent the progression of non-exudative AMD
‧Summary of studies and results from current clinical trials
‧A collaboration of world renowned experts in the field with over 75 contributors
13 new chapters include:
‧New genetics and treatment chapter will cover the responses of different variants to treatment.
‧Oxidative Stress is moving along quickly as a new target for therapy. This is important in the pathophysiology for AMD and CNV (choroidal neovascularization—a common symptom of wet AMD).
‧Polypoidal and RAP chapters are included as more info. Warrants separate chapters of these variants of AMD.
‧How to analyze OCT will cover the analysis software and other programs that help in managing patients.
‧Microperimetry and psychophysical testing will cover new ways to track geographic atrophy progression (includes newly uncovered data).
‧Non-VEGF pathways will cover complement paths, nicotinic, etc.—important new treatment paths.
‧Radiation and Steroid chapters will address new treatments that help in CNV management.
‧Retinal stem cells will cover new information and potential avenues of future treatment.
Jennifer I. Lim, M.D.is a professor of ophthalmology, Department of Ophthalmology; Director of the Retina Service; Marion H. Schenk, Esq. Chair in Ophthalmology for Research of the Aging Eye, at the University of Illinois at Chicago.
Dr Lim has contributed to over 90 courses, and has published over 200 academic papers, contributed to over 20 book chapters and published 4 books in total. She has given over 150 presentations at scientific meetings and has been invited to over 130 lectures/visiting professorships. Dr Lim is a reviewer for a number of academic journals including the American Journal of Ophthalmology, Retina, and the British Journal of Ophthalmology. She is currently a committee member for the Macula Society, American Society of Retinal Specialists, and American Academy of Ophthalmology.
‧Marion H. Schenk, Esq., Chair in Ophthalmology for Research of the Aging Eye, 2010
‧Best Doctors in America 2010-2011 (initially and continuously selected since 1994)